Welcome to our dedicated page for Aclarion SEC filings (Ticker: ACONW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aclarion, Inc. filings document material events and governance for a commercial-stage healthcare technology issuer with Nasdaq-listed common stock and warrants. Recent Form 8-K reports cover capital actions such as a share repurchase authorization, executive finance leadership transition, employment agreement terms and Regulation FD communications.
The company's regulatory record also includes annual meeting and stockholder-vote disclosures, director elections, emerging growth company status and common stock information. These filings frame Aclarion's public reporting around its healthcare technology business, governance controls, officer appointments and capital-structure actions.
Aclarion, Inc. (ACON) director Amanda M. Williams reported a purchase of Aclarion common stock. On August 17, 2026, she bought 5,857 shares of common stock in a public market transaction at $2.73 per share. Following this open-market purchase, she directly owns 25,857 shares of Aclarion common stock. The filing indicates the trade was not made under a Rule 10b5-1 trading plan.
Aclarion, Inc. CFO Gregory A. Gould reported an open-market purchase of 10,000 shares of ACON common stock on August 14, 2026 at $2.45 per share, as disclosed in a footnote stating the shares were bought on the public market. Following this transaction, he directly holds 60,000 common shares. The transaction is classified as a purchase in an open market or private transaction and is not reported as executed under a Rule 10b5-1 trading plan.
Aclarion, Inc. director Ryan Bond reported an open-market purchase of Aclarion common stock. On August 13, 2026, he purchased 21,122 shares of common stock at $2.37 per share on the public market. Following this transaction, his direct holdings increased to 76,122 shares of Aclarion common stock. The filing indicates the Rule 10b5-1 trading-plan checkbox was not selected.
Aclarion, Inc. director Wesemann William purchased additional ACON common stock. On August 13, 2026, he bought 2,150 shares of common stock in a public market transaction at $2.34 per share, increasing his direct holdings to 23,713 shares. The filing indicates this transaction was not made pursuant to a Rule 10b5-1 trading plan.
Aclarion, Inc. director Neal David K reported an open-market purchase of 7,500 shares of Aclarion common stock on August 13, 2026 at $2.40 per share. Following this transaction, he directly holds 30,002 shares of Aclarion common stock.
Aclarion, Inc. Chief Executive Officer Brent Ness purchased 5,234 shares of ACON common stock on 08/13/2026 in a public market transaction at $2.31 per share. Following this open-market purchase, he directly owns 111,534 shares of Aclarion common stock.
Aclarion, Inc., an early-stage healthcare technology company, generated modest revenue but continued sizable losses in the quarter ended June 30, 2026. Q2 revenue was $25,208 (first-half $46,348), while net losses were $2.7 million for the quarter and $5.6 million year‑to‑date.
Operating expenses rose sharply as the company invested in commercialization and product development. First-half operating expenses reached $5.9 million, driven by higher sales and marketing spending around the NOCISCAN report and CLARITY Trial, increased R&D, and greater legal, investor relations, and Delaware franchise tax costs.
Despite negative operating cash flow of $5.3 million in the first half, Aclarion strengthened its balance sheet via a January 2026 registered direct offering of common stock and pre-funded warrants, raising about $10.4 million. Cash, cash equivalents and restricted cash totaled $16.3 million at June 30, 2026, and management believes this will fund operations for at least twelve months, though additional capital may be needed to fully execute its strategy. Common shares outstanding increased to 2,462,250 at June 30, 2026, reflecting equity financings and warrant exercises.
Bond Ryan reported acquisition or exercise transactions in this Form 4 filing.
Aclarion, Inc. reported that Chief Strategy Officer Ryan Bond received an equity grant of 55,000 restricted stock units on 6/11/2026 under the company’s equity incentive plan. Each RSU equals one share of common stock and 100% of the award is scheduled to vest on 6/1/2027, with full acceleration upon a qualifying change of control.
Sequira Amanda Mae reported acquisition or exercise transactions in this Form 4 filing.
Aclarion, Inc. director Amanda Mae Sequira received an award of 20,000 restricted stock units (RSUs) of common stock on 6/11/2026 under the company’s equity incentive plan. Each RSU represents the right to receive one Aclarion share if vesting conditions are met.
The filing states that 100% of these RSUs will vest on 6/1/2027. Any RSUs still unvested at that time will also fully vest if a change of control, as defined in the equity incentive plan, occurs before then. After this grant, Sequira directly holds 20,000 shares/RSUs.
Breidbart Scott reported acquisition or exercise transactions in this Form 4 filing.
Aclarion, Inc. director Scott Breidbart received an equity grant in the form of restricted stock units. He was awarded 20,000 RSUs on 6/11/2026 under the company’s equity incentive plan, with each unit representing one share of ACON common stock.
All of these RSUs are scheduled to vest on 6/1/2027, meaning he will receive the underlying shares at that time if conditions are met. Any unvested RSUs will fully vest earlier if there is a change of control as defined in the plan. Following this award, Breidbart directly holds 25,664 shares.